Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States

Figures & data

Figure 1. Treatment flow diagram for the base case. Abbreviations: OAB, overactive bladder; PTNS, percutaneous tibial nerve stimulation; SNM, sacral neuromodulation.

Table 1. Cost-effectiveness results for base case using a lifetime horizon.

							Vibegron 75 mg vs Comparator
Treatment	Pharmacy costs*	OAB comorbidity	ACB comorbidity	AE costs	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER
Commercial Payor
Vibegron 75 mg	$4,568	$24,913	$9,785	$1.34	$39,269	21.975	‒	‒	‒
Mirabegron 25 mg	$3,629	$24,931	$9,983	$3.29	$38,546	21.970	$723	0.005	$141,957
Mirabegron 50 mg	$4,281	$24,928	$10,002	$7.11	$39,218	21.970	$51	0.005	$9,311
Anticholinergic basket	$1,954	$24,908	$10,281	$9.00	$37,152	21.957	$2,117	0.018	$118,121
Medicare
Vibegron 75 mg	$3,646	$17,833	$5,353	$0.97	$26,833	13.351	‒	‒	‒
Mirabegron 25 mg	$2,726	$17,849	$5,497	$2.39	$26,075	13.343	$758	0.008	$99,150
Mirabegron 50 mg	$3,363	$17,843	$5,511	$5.17	$26,722	13.342	$111	0.009	$12,154
Anticholinergic basket	$1,070	$17,800	$5,706	$6.55	$24,583	13.314	$2,250	0.037	$60,756

Abbreviations: ACB, anticholinergic burden; AE, adverse event; ICER, incremental cost-effectiveness ratio; OAB, overactive bladder; QALY, quality-adjusted life year.

*Represents the total treatment costs from first-, second-, and third-line treatments of the OAB cohort starting on each of the 15 modeled OAB treatments.

Figure 2. OWSAs for vibegron 75 mg vs (a) mirabegron 25 mg* and (b) mirabegron 50 mg^† from the commercial payor perspective. Abbreviations: ACB, anticholinergic burden; AE, adverse event; OAB, overactive bladder; OWSA, one-way sensitivity analysis. * Base case = $141,957. ^† Base case = $9,311.

Figure 3. OWSAs for vibegron 75 mg vs (a) mirabegron 25 mg* and (b) mirabegron 50 mg^† from the Medicare perspective. Abbreviations: ACB, anticholinergic burden; AE, adverse event; OAB, overactive bladder; OWSA, one-way sensitivity analysis. * Base case = $99,150. ^† Base case = $12,153.

Figure 4. OWSAs for vibegron 75 mg vs an anticholinergic basket from a (a) commercial payor* and (b) Medicare^† perspective. Abbreviations: ACB, anticholinergic burden; AE, adverse event; OAB, overactive bladder; OWSA, one-way sensitivity analysis. * Base case = $118,121. ^† Base case = $60,756.

Figure 5. Cost-effectiveness acceptability for vibegron vs (a) mirabegron 25 mg and (b) mirabegron 50 mg for commercial payors. Abbreviation: WTP, willingness-to-pay.

Figure 6. Cost-effectiveness acceptability for vibegron vs (a) mirabegron 25 mg and (b) mirabegron 50 mg for Medicare. Abbreviation: WTP, willingness-to-pay.